- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
GLP-1, SGLT2 medications may lower risk of future MI and repeat stroke among stroke survivors: Study
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association’s Scientific Sessions 2024. The meeting, Nov. 16-18, 2024, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
“Unfortunately, a quarter of people who survive a stroke will have another stroke, and they are also at risk for other cardiovascular events such as a heart attack since many of the risk factors of a stroke are also associated with other forms of heart disease,” said lead study author M. Ali Sheffeh, M.D., an internal medicine physician and research scholar at the Mayo Clinic in Rochester, Minnesota. “Managing these risks, as well as looking at novel approaches to help lower the chances of another stroke, heart attack or death among this population are all critical steps in increasing stroke survival and improving the quality of life for people who have had a stroke.”
In this study, Sheffeh and colleagues evaluated whether two classes of medications for treating Type 2 diabetes are associated with a decreased risk of heart attacks, secondary stroke or death in stroke survivors.
One of the classes of medications – glucagon-like peptide-1 receptor agonists (GLP-1) – treats Type 2 diabetes by stimulating insulin release by the pancreas, delaying gastric emptying, and decreasing the release of glucagon, a hormone in the body that raises blood sugar.
The GLP-1 medications liraglutide and semaglutide, as well as the dual GLP-1 and glucose-independent insulinotropic polypeptide (GIP) tirzepatide, are approved by the U.S. Food & Drug Administration for weight loss and to reduce the risk of cardiovascular disease for people with obesity or overweight.
The other medication class, sodium-glucose cotransporter 2 inhibitors (SGLT2), lowers blood sugar levels by inducing the kidneys to remove excess glucose from the body through the urine. The SGLT2 medications canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are approved by the FDA for the treatment of Type 2 diabetes.
To analyze the impact of these two classes of medications, this study reviewed medical records for more than 7,000 adults who had clot-caused, or ischemic, strokes between January 2000 and June 2022. All participants had received stroke care at hospitals within multiple health systems in Minnesota or Wisconsin. Researchers assessed outcomes for people who were prescribed either a GLP-1 or an SGLT2 medication after their initial stroke to determine if there was a potential impact on the risk of having a second stroke, a heart attack or dying.
After an average follow-up of three years, the analysis found:
Adults who were taking either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of having a heart attack.
Adults who were taking an SGLT2 were also at a 67% lower risk of having another stroke.
All decreased risks noted were present even when researchers accounted for other factors that may have affected or increased some patients’ risk. These included age, sex, smoking status, hypertension status, Type 2 diabetes status, peripheral artery disease, hyperlipidemia, chronic kidney disease and a history of heart attack or a history of heart failure.
Within the entire study period, the death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8%, compared to 54% among patients who did not take either class of medication. The rate of heart attacks among patients receiving either medication was also 1.5%, compared to 6.1% among patients not taking either class of medication.
The rate of having another stroke was similar between patients who did and did not receive either medication, at approximately 6%.
“When comparing multiple variables, we can still conclude that treatment with either medication was associated with lower risk of recurrent stroke even though the rate was similar between patients who did and did not receive either medication,” Sheffeh said. He noted that the medications significantly lowered the risk of recurrent stroke in an analysis that compared multiple variables, including patients’ risk factors for recurrent stroke—age, sex, hypertension status, Type 2 diabetes status, peripheral artery disease and a history of heart attack or a history of heart failure. However, the risk of recurrent stroke was not significantly lower in an analysis comparing medication use with recurrent stroke and no additional variables.
“The potential protective effects of the medications were hidden because those in the treatment group may have more high-risk features than the patients who were not taking either medication, hiding any protective effect. What the multivariate adjusting does is account for those differences and tease out any independent effect,” Sheffeh said. “The results of the study are consistent with other research about the preventive role of these medications against cardiovascular disease in people with obesity or heart failure.”
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751